Renaissance Herbs, Inc., Chatsworth, CA, has introduced new delivery modalities and innovative uses for HCA under an exclusive licensing agreement with Gly­kon Technologies Group, LLC. This a­greement incorporates 13 U.S. patents and patents pending, plus additional proprietary technology. Glykon Technologies Group discovered and holds the rights to make claims regarding the impact of HCA on the regulation of insulin and blood sugar (Syndrome X), modulation of leptin and glucocorticoids, improvements in bone mineralization, the regulation of immune function and inflammation. The company also has patented multiple technologies greatly expanding the range of available delivery forms for HCA as well as improving its assimilation and activity.